Emanuele Trovato

Siena, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 94 publications

Predictors of outcomes and satisfaction with tirbanibulin in actinic keratosis: a multicenter real-world study.

Predictors of outcomes and satisfaction with tirbanibulin in actinic keratosis: a multicenter real-world study.

Journal: Italian journal of dermatology and venereology

Published: August 24, 2026

Topical treatment of psoriasis with calcipotriol/betamethasone dipropionate cream in real-life clinical practice: expert opinion.

Topical treatment of psoriasis with calcipotriol/betamethasone dipropionate cream in real-life clinical practice: expert opinion.

Journal: Italian journal of dermatology and venereology

Published: August 24, 2026

Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study.

Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study.

Journal: The Journal of dermatological treatment

Published: July 29, 2026

Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS).

Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS).

Journal: Dermatology and therapy

Published: July 14, 2026

Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.

Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.

Journal: The British journal of dermatology

Published: May 16, 2026

Systemic Immune-Inflammation Index (SII) as a Predictive Biomarker of Therapeutic Response in Psoriasis: A Retrospective Comparative Analysis of Anti-TNF, Anti-IL-17, and Anti-IL-23 Agents.

Systemic Immune-Inflammation Index (SII) as a Predictive Biomarker of Therapeutic Response in Psoriasis: A Retrospective Comparative Analysis of Anti-TNF, Anti-IL-17, and Anti-IL-23 Agents.

Journal: Journal of personalized medicine

Published: April 29, 2026

Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.

Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: April 11, 2026

Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis.

Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis.

Journal: Dermatology and therapy

Published: April 10, 2026

Effectiveness of scabies treatments in Italy (SCAB-net): a prospective observational study.

Effectiveness of scabies treatments in Italy (SCAB-net): a prospective observational study.

Journal: The Lancet. Infectious diseases

Published: February 09, 2026

Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes-IL PSO (Italian Landscape Psoriasis).

Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes-IL PSO (Italian Landscape Psoriasis).

Journal: Dermatology and therapy

Published: December 26, 2025

Forty-eight-week safety of bimekizumab in psoriasis: focus on infectious comorbidities.

Forty-eight-week safety of bimekizumab in psoriasis: focus on infectious comorbidities.

Journal: Italian journal of dermatology and venereology

Published: December 11, 2025

Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis).

Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis).

Journal: Dermatology and therapy

Published: December 01, 2025

Showing 1-12 of 94

Last Updated: 09/26/2026